195 related articles for article (PubMed ID: 38170551)
41. Advanced Triple-Negative Breast Cancer.
Patel G; Prince A; Harries M
Semin Oncol Nurs; 2024 Feb; 40(1):151548. PubMed ID: 38008654
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Sternschuss M; Yerushalmi R; Saleh RR; Amir E; Goldvaser H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3369-3379. PubMed ID: 33745080
[TBL] [Abstract][Full Text] [Related]
43. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
Cyprian FS; Akhtar S; Gatalica Z; Vranic S
Bosn J Basic Med Sci; 2019 Aug; 19(3):227-233. PubMed ID: 30915922
[TBL] [Abstract][Full Text] [Related]
44. Antibody-Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer.
Al Jarroudi O; El Bairi K; Curigliano G; Afqir S
Cancer Treat Res; 2023; 188():1-27. PubMed ID: 38175340
[TBL] [Abstract][Full Text] [Related]
45. Triple-negative breast cancer: recent treatment advances.
Bergin ART; Loi S
F1000Res; 2019; 8():. PubMed ID: 31448088
[TBL] [Abstract][Full Text] [Related]
46. Current usage of pembrolizumab in triple negative breast cancer (TNBC).
O'Rourke H; Hart C; De Boer RH
Expert Rev Anticancer Ther; 2024 May; 24(5):253-261. PubMed ID: 38594892
[TBL] [Abstract][Full Text] [Related]
47. Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021.
Trapani D; Curigliano G
Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S54-S57. PubMed ID: 34920925
[TBL] [Abstract][Full Text] [Related]
48. New Therapeutic Strategies for Triple-Negative Breast Cancer.
Székely B; Silber AL; Pusztai L
Oncology (Williston Park); 2017 Feb; 31(2):130-7. PubMed ID: 28205193
[TBL] [Abstract][Full Text] [Related]
49. Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches.
Geurts V; Kok M
Curr Treat Options Oncol; 2023 Jun; 24(6):628-643. PubMed ID: 37079257
[TBL] [Abstract][Full Text] [Related]
50. Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis.
Püsküllüoğlu M; Rudzińska A; Pacholczak-Madej R
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188991. PubMed ID: 37758021
[TBL] [Abstract][Full Text] [Related]
51. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape.
Uliano J; Nicolò E; Corvaja C; Taurelli Salimbeni B; Trapani D; Curigliano G
Expert Rev Clin Pharmacol; 2022 Dec; 15(12):1399-1413. PubMed ID: 36317756
[TBL] [Abstract][Full Text] [Related]
52. Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer.
Ren Y; Song J; Li X; Luo N
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012144
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapeutic interventions of Triple Negative Breast Cancer.
Li Z; Qiu Y; Lu W; Jiang Y; Wang J
J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
[TBL] [Abstract][Full Text] [Related]
54. Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis.
Rizzo A; Cusmai A; Massafra R; Bove S; Comes MC; Fanizzi A; Rinaldi L; Acquafredda S; Gadaleta-Caldarola G; Oreste D; Zito A; Giotta F; Lorusso V; Palmiotti G
Cells; 2022 Jun; 11(12):. PubMed ID: 35740985
[TBL] [Abstract][Full Text] [Related]
55. Recent advances in triple negative breast cancer: the immunotherapy era.
Marra A; Viale G; Curigliano G
BMC Med; 2019 May; 17(1):90. PubMed ID: 31068190
[TBL] [Abstract][Full Text] [Related]
56. Neoadjuvant radiotherapy in ER
Bruss C; Albert V; Seitz S; Blaimer S; Kellner K; Pohl F; Ortmann O; Brockhoff G; Wege AK
Front Immunol; 2024; 15():1355130. PubMed ID: 38742103
[TBL] [Abstract][Full Text] [Related]
57. Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy.
Jeong JH; Kim SB
Breast; 2022 Dec; 66():199-203. PubMed ID: 36327625
[TBL] [Abstract][Full Text] [Related]
58. Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer.
Gonzalez-Ericsson PI; Wulfkhule JD; Gallagher RI; Sun X; Axelrod ML; Sheng Q; Luo N; Gomez H; Sanchez V; Sanders M; Pusztai L; Petricoin E; Blenman KRM; Balko JM;
Clin Cancer Res; 2021 Oct; 27(19):5299-5306. PubMed ID: 34315723
[TBL] [Abstract][Full Text] [Related]
59. Advances in the systemic treatment of triple-negative breast cancer.
Lebert JM; Lester R; Powell E; Seal M; McCarthy J
Curr Oncol; 2018 Jun; 25(Suppl 1):S142-S150. PubMed ID: 29910657
[TBL] [Abstract][Full Text] [Related]
60. Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies.
Sakach E; O'Regan R; Meisel J; Li X
Clin Breast Cancer; 2021 Dec; 21(6):509-520. PubMed ID: 34629314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
